About tscan therapeutics inc - TCRX
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Waltham, MA.
TCRX At a Glance
TScan Therapeutics, Inc.
830 Winter Street
Waltham, Massachusetts 02451
| Phone | 1-857-399-9500 | Revenue | 10.33M | |
| Industry | Biotechnology | Net Income | -129,766,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 266.655% | |
| Fiscal Year-end | 12 / 2026 | Employees | 142 | |
| View SEC Filings |
TCRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.569 |
| Price to Book Ratio | 0.462 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.538 |
| Enterprise Value to Sales | 6.926 |
| Total Debt to Enterprise Value | 1.316 |
TCRX Efficiency
| Revenue/Employee | 72,711.268 |
| Income Per Employee | -913,845.07 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.034 |
TCRX Liquidity
| Current Ratio | 8.409 |
| Quick Ratio | 8.409 |
| Cash Ratio | 8.152 |
TCRX Profitability
| Gross Margin | 72.242 |
| Operating Margin | -1,315.38 |
| Pretax Margin | -1,256.814 |
| Net Margin | -1,256.814 |
| Return on Assets | -42.154 |
| Return on Equity | -71.282 |
| Return on Total Capital | -59.728 |
| Return on Invested Capital | -47.719 |
TCRX Capital Structure
| Total Debt to Total Equity | 76.459 |
| Total Debt to Total Capital | 43.329 |
| Total Debt to Total Assets | 38.492 |
| Long-Term Debt to Equity | 70.637 |
| Long-Term Debt to Total Capital | 40.031 |